Marksans Pharma announced a significant development for its UK operations. The company's wholly-owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two key products: Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets.

Regulatory Milestone

This regulatory approval marks an important step for Marksans Pharma's presence in the UK pharmaceutical market. Moxonidine, the active ingredient in these newly approved tablets, is primarily used for the treatment of mild to moderate essential hypertension. The authorization allows Relonchem Limited to market these pharmaceutical products in the UK, potentially expanding Marksans Pharma's footprint in the cardiovascular therapeutic segment.

Strategic Implications

The approval aligns with Marksans Pharma's strategy to strengthen its global generic pharmaceutical portfolio. With manufacturing facilities approved by leading regulatory agencies, including the USFDA, UKMHRA, and Australian TGA, this new authorization further solidifies the company's position in regulated markets.

Company Profile

Marksans Pharma Limited, headquartered in Mumbai, India, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company's product portfolio spans major therapeutic segments, including cardiovascular system (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterological, and anti-allergies.

Investor Relations

In related news, Marksans Pharma has scheduled an investor/analyst conference for September 23, 2025, at 10:00 AM IST. The physical meeting, part of the Pharma & Healthcare Conference by DAM Capital, will be held at Trident BKC. This event underscores the company's commitment to maintaining transparent communication with its stakeholders.

As Marksans Pharma continues to expand its product offerings and market presence, this latest approval for Moxonidine tablets represents another step in the company's growth strategy in the competitive global pharmaceutical landscape.

Marksans Pharma Limited, a prominent player in the pharmaceuticals segment, has announced its audited financial results for the quarter and year ended March 31, 2024, showcasing robust growth across key financial metrics.

Standalone Performance

On a standalone basis, Marksans Pharma demonstrated significant improvement in its financial performance:

Consolidated Results

The company's consolidated financial results also reflected strong growth:

Dividend Announcement

In a move that will likely please shareholders, the Board of Directors has recommended a final dividend of Rs 0.60 per equity share for the financial year 2023-24. This dividend is subject to approval at the upcoming Annual General Meeting.

Auditor's Opinion

It's worth noting that the company's auditors have provided an unmodified opinion on both the standalone and consolidated financial statements, indicating a clean bill of health for Marksans Pharma's financial reporting.

Strategic Acquisition

In a significant development that occurred in April 2023, Marksans Pharma completed the acquisition of a manufacturing facility in Goa from Tevapharm India Private Limited for Rs 779.47 million. This strategic move is expected to enhance the company's manufacturing capabilities and potentially contribute to future growth.

The impressive financial results, coupled with the strategic acquisition and the recommended dividend, underscore Marksans Pharma's strong position in the pharmaceutical industry and its commitment to delivering value to shareholders.